RARE:NASDAQ
Ultragenyx Pharmaceutical Inc
16,08 US$
arrow_downward
-1,17%(-0,19) 1D
13 ნოე, 16:00:00 GMT-5 · USD
search
All symbols
| Symbol | Price | Change | % Change |
|---|
insights_autoGenerating top insights for RARE...
Open
16,30 US$
High
16,32 US$
Low
15,85 US$
Mkt. cap
1,64 მლრდ.
Avg. vol.
3,71 მლნ.
Volume
1,68 მლნ.
52-wk high
39,89 US$
52-wk low
12,73 US$
EPS
-5,19 US$
Beta
0,37
Shares outstanding
101,92 მლნ.
No. of employees
1 ათ.
Open
16,30 US$
High
16,32 US$
Low
15,85 US$
Mkt. cap
1,64 მლრდ.
Avg. vol.
3,71 მლნ.
Volume
1,68 მლნ.
52-wk high
39,89 US$
52-wk low
12,73 US$
EPS
-5,19 US$
Beta
0,37
Shares outstanding
101,92 მლნ.
No. of employees
1 ათ.
News stories
From web sources and news partners
Yahoo Finance
·
1 საათის წინ
The S&P 500 Has Gone 18 Months Without a 10% Drop. Here's How the Next Year Has Gone After Streaks This Long.
Howl.Link
·
2 საათის წინ
Weekly Market Outlook – Not A Decisive Reversal Effort - TalkMarkets
Moneycontrol.com
·
1 საათის წინ
SpaceX’s S&P 500 bid gets new life as Musk pitches Tesla merger
CNBC
·
1 დღის წინ
Is a bottom in for the Nasdaq-100? Charts to watch
Profile
Ultragenyx Pharmaceutical Inc. is an American biopharmaceutical company involved in the research and development of novel products for treatment of rare and ultra-rare genetic diseases for which there are typically no approved treatments and high unmet medical need. The company works with multiple drug modalities including biologics, small molecule, gene therapies, and ASO and mRNAs in the disease categories of bone, endocrine, metabolic, muscle and CNS diseases.
Ultragenyx is based in Novato, CA and Brisbane, CA and has a presence in the Boston area, including a gene therapy plant under construction as of 2021. The company’s Latin American headquarters is located in Miami.
Ultragenyx collaborates on product development with other companies including GeneTX, Kyowa Hakko Kirin, Mereo Biopharma and Daiichi Sankyo. Ultragenyx has three products Burosumab, Triheptanoin and Vestronidase alfa that have received FDA approval and several others currently in clinical trials. The company also holds the non-US commercial rights to Regeneron’s evinacumab-dgnb, which is approved by the FDA and EMA. Wikipedia
About Ultragenyx Pharmaceutical Inc
CEOემილ კაკისი
Employees1,37 ათ.
Founded2010
HeadquartersNovato, კალიფორნია, ამერიკის შეერთებული შტატები
SectorHealth Care
Industry-
Websiteultragenyx.com